10 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 10 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 3 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Genmab and provided 12-month price targets. The average target is $50.0, accompanied by a high estimate of $53.00 and a low estimate of $47.00. Witnessing a positive shift, the current average has risen by 0.81% from the previous average price target of $49.60.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of...
Login or create a forever free account to read this news
Sign up/Log in